Sutureless valves have recently been developed to streamline surgical aortic valve replacement (SAVR) procedures, with the hope that shorter operations lead to better outcomes. But a new study in the Journal of the American College of Cardiology suggests quicker is not always better.

In a blog published March 29 by Health Affairs, four researchers expressed the need for creative reimbursement systems to “promote accountability” for outcomes related to devices that treat cardiovascular disease (CVD).

Socially isolated and lonely individuals face increased risk for acute myocardial infarction (AMI) and stroke compared to those with personal networks, according to new research published online March 27 in Heart. Those with a history of AMI and stroke are also at an increased risk for death.

The speed with which IV diuretics were administered to people with acute heart failure (AHF) didn’t appear to make a difference in short- or intermediate-term mortality rates, according to a study of 2,761 Korean patients.

Todd A. Trapp will take over as CFO of Abiomed on April 9, the company announced March 30.

Death rates from heart disease decreased by 68 percent for Americans from 1968 to 2015, according to a new analysis, but the mortality decline was greater for whites than blacks.

Diagnosed diabetes in the U.S. cost a total of $327 billion in 2017, according to a new report commissioned by the American Diabetes Association published online March 22 in Diabetes Care.

The American Heart Association (AHA) issued a statement March 29 applauding Congress for including funding increases for federal programs aimed at combating cardiovascular disease in its final omnibus spending bill.

Patients who developed new-onset postoperative atrial fibrillation (POAF) after coronary artery bypass graft (CABG) surgery showed a 33 percent reduced risk of thromboembolism long-term when compared to those with nonsurgical AFib, according to a study published March 28 in JAMA Cardiology.

ABBOTT PARK, Ill., March 29, 2018 — Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF trial will study whether the CardioMEMS device can improve survival and quality of life for people living with New York Heart Association (NYHA) Class II – IV heart failure.